Recruiting | Phase III
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
To confirm the effectiveness of the combination of Cediranib and Olaparib to the standard chemotherapy.
Group 1: Standard of care chemotherapy
Group 2: Combination of oral medications, Cediranib and Olaparib taken daily
Group 3: Cediranib taken daily
Key Participation Requirements:
19 years and older
Recurrent ovarian, primary peritoneal, or fallopian tube cancer
BRCA testing through Myriad
No more than three prior treatments.
May not have previously received a PARP-inhibitor.
Patients must sign an approved informed consent and authorization permitting release of personal health information.
Methodist Health System Trial Code:
For more information, visit the U.S. National Library of Medicine clinical trial database.